(237 days)
Not Found
No Reference Device(s) K/DEN number was identified in the provided text.
No
The summary describes a physical medical device (catheter) and its intended use in a surgical procedure. There is no mention of software, algorithms, image processing, AI, or ML. The performance studies focus on equivalence to predicate devices, not algorithmic performance metrics.
Yes
The device is intended to perfuse the aorta, which is a therapeutic intervention to maintain blood flow during a medical procedure.
No
The device, the Cardeon® Aegis™ Catheter, is described as intended to "perfuse the aorta during open chest (sternotomy) procedures on cardiopulmonary bypass." This indicates a therapeutic or interventional function, not a diagnostic one. There is no mention of it being used to identify or analyze medical conditions.
No
The device description explicitly states "Catheter, cannula and tubing, vascular, cardiopulmonary bypass," which are physical hardware components.
Based on the provided information, the Cardeon® Aegis™ Catheter is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is used to "perfuse the aorta during open chest (sternotomy) procedures on cardiopulmonary bypass". This describes a device used in vivo (within the living body) during a surgical procedure.
- Device Description: The description "Catheter, cannula and tubing, vascular, cardiopulmonary bypass" further supports its use in a surgical setting, directly interacting with the vascular system.
- Lack of IVD Characteristics: IVD devices are used to examine specimens (like blood, urine, tissue) in vitro (outside the body) to provide information for diagnosis, monitoring, or screening. The provided information does not mention any such use or interaction with patient specimens outside the body.
Therefore, the Cardeon® Aegis™ Catheter is a medical device used in vivo during surgery, not an IVD.
N/A
Intended Use / Indications for Use
The Cardeon® Aegis™ Catheter is intended to perfuse the aorta during open chest (sternotomy) procedures on cardiopulmonary bypass up to 6 hours.
Product codes
DWF
Device Description
Not Found
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
aorta
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Results of product testing demonstrated that the Aegis Catheter functions as safely and effectively as a predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.4210 Cardiopulmonary bypass vascular catheter, cannula, or tubing.
(a)
Identification. A cardiopulmonary bypass vascular catheter, cannula, or tubing is a device used in cardiopulmonary surgery to cannulate the vessels, perfuse the coronary arteries, and to interconnect the catheters and cannulas with an oxygenator. The device includes accessory bypass equipment.(b)
Classification. Class II (performance standards).
0
510(k) - Cardeon Aegis™ Catheter
APPENDIX G
JUN 2 4 2002
510(k) SUMMARY
510(k) number:
This summary of information is being provided in accordance with 21 CFR 807.92(a).
| Applicant Information: | Cardeon Corporation
10161 Bubb Road
Cupertino, CA 95014 |
|------------------------|----------------------------------------------------------------|
| Contact Person: | Jane Beggs
Regulatory Affairs
Cardeon Corporation |
| Date: | 29 October 2001 |
| Device Trade Name: | Cardeon® Aegis™ Catheter |
| Device Common Name | Catheter, cannula and tubing, vascular, cardiopulmonary bypass |
| Regulation No.: | 870.4210 |
| Classification / Code: | Class II / DWF |
Indications for Use: The Cardeon® Aegis™ Catheter is intended to perfuse the aorta during open chest (sternotomy) procedures on cardiopulmonary bypass up to 6 hours.
Summary of Substantial Equivalence: The Aegis Catheter is substantially equivalent to currently marketed devices used to directly cannulate the aorta and return perfusion to patients undergoing general cardiac surgery. Perfusion is achieved through standard connections to the extracorporeal circuit. Substantial equivalence is supported through comparison with several marketed devices with the same indications for use, including arterial return cannulae with directed flow (specified flow pattern). Differences between the Aegis Catheter and other devices do not alter or diminish the rate of arterial return required during cardiopulmonary bypass. Based on comparisons to currently marketed devices and device performance testing. the Cardeon Aegis Catheter is substantially equivalent to predicate devices with regard to intended use/indications, device performance and technological characteristics.
The determination of substantial equivalence was also based on an Product Testing: assessment of device biocompatibility, in vitro and in vivo performance. Results of product testing demonstrated that the Aegis Catheter functions as safely and effectively as a predicate devices.
1
Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized caduceus symbol, which is a staff with two snakes coiled around it. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus symbol.
Public Health Service
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
JUN 2 4 2002
Cardeon Corp. c/o Ms. Jane Beggs 10161 Bubb Road Cupertino, CA 95014
Re: K013593
Cardeon® Aegis™ Catheter Regulation Number: 870.4210 Regulation Name: Cardiopulmonary Bypass Vascular Catheter, Cannula, and Tubing Regulatory Class: Class II (two) Product Code: 74 DWF Dated: May 3, 2002 Received: May 6, 2002
Dear Ms. Beggs:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
2
Page 2 - Ms. Jane Beggs
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.qov/cdrh/dsma/dsmamain.html
Sincerely yours,
Dr. Tiller, Ph.D.
Donna-Bea Tillman, Ph.D. Acting Director Division of Cardiovascular and Respiratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Kols593
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Page 1.of 1
Device Name: Cardeon® Aegis™ Catheter
Indications for Use:
The Cardeon Aegis™ Catheter is intended to perfuse the aorta during open chest procedures on cardiopulmonary bypass up to 6 hours.
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | OR | Over-the Counter Use | ||
|---|---|---|---|---|
| ------------------ | -- | ---- | ---------------------- | -- |
(Division Sign-Off)
Division of Cardiovascular and Respiratory Devices
| 510(k) Number | K013593 |
|---|---|
| --------------- | --------- |